Absorbed Doses per Unit Activity to Target Organs Evaluated Using the 3 Methods
| Absorbed dose | |||
|---|---|---|---|
| Target organ | Method A | Method B | Method C |
| Heart wall | 2.1 (1.1–5.4) | 2.2 (1.0–5.4) | NE |
| Lungs | 1.7 (0.3–3.5) | 1.7 (0.4–3.5) | 3.2 (0.8–5.1) |
| Liver | 2.8 (1.8–10.6) | 3.0 (1.6–8.0) | 2.5 (2.1–8.3) |
| Spleen | 1.9 (0.8–5.0) | 3.9 (2.4–7.4) | 6.1 (3.1–10.2) |
| Kidneys | 1.7 (0.6–3.8) | 2.3 (0.9–5.0) | 4.0 (2.3–8.1) |
| Red marrow | 0.8 (0.4–1.0) | 0.8 (0.5–1.0) | 0.8 (0.5–1.6) |
| Testes (17 patients) | 2.8 (1.3–4.7) | 2.8 (1.3–4.7) | 4.7 (2.5–9.8) |
| Other organs | 0.4 (0.3–0.6) | 0.4 (0.3–0.6) | 0.5 (0.4–0.6) |
| Total body | 0.5 (0.4–0.8) | 0.6 (0.5–0.8) | 0.6 (0.5–0.8) |
NE = not evaluable.
Data are median values and ranges of variability (mGy/MBq) among patients (4 patients of group I, 4 patients of group II, and 14 patients of group III).